Teaneck, NJ, United States of America

Howard R Levin

This inventor holds 131 USPTO granted patents and 31 published patent applications, plus 6 CIPO patents and 28 EPO patents, primarily in Renal Neuromodulation (CPC class A61B18-1492). Top assignees: Medtronic Ardian Luxembourg S.a.r.l., Chf Solutions, Inc., Ardian, Inc.. Active years: 1999-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Howard R Levin. Retrieved from https://idiyas.com/inventor/howard-r-levin

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 131 

% Patents Active = 63.4

 

 

Average Co-Inventor Count = 3.7

ph-index = 51

Forward Citations = 13,999(Granted Patents)

Forward Citations (Not Self Cited) = 12,458(Dec 10, 2025)


Inventors with similar research interests:

🔬 See more inventors

Company Filing History:


Years Active: 1999-2026

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Renal Neuromodulation
Fluid Management
Breathing Disorders
Phrenic Nerve Modulation
Cardiac Disorders
Urine Output Monitoring
Thermal Neuromodulation
Extravascular Techniques
Catheter-Based Systems
Neuromodulatory Agents
Bilateral Techniques
Patient Hydration
131 patents (USPTO):Explore Patents

Title: Howard R. Levin: A Pioneer in Renal Neuromodulation

Introduction

Howard R. Levin, residing in Teaneck, NJ, is an esteemed inventor with an impressive portfolio of 127 patents. His innovations within the medical technology field have significant implications for treating various renal and cardiovascular conditions, particularly through advanced neuromodulation techniques.

Latest Patents

Levin's latest patents delve into the realm of bilateral renal neuromodulation. He has developed methods and apparatuses aimed at treating hypertension. These techniques include the use of pulsed electric fields, localized drug delivery, high-frequency ultrasound, and thermal techniques. The innovative approaches may accomplish irreversible electroporation or electrofusion, induce necrosis and apoptosis, and alter gene expression in targeted neural fibers. Notably, his bilateral approach to neuromodulation is designed to enhance therapeutic effects compared to unilateral treatments, focusing on neural fibers that contribute to renal function.

Another significant patent focuses on renal neuromodulation through the application of a pulsed electric field. This invention aims to prevent the expansion of acute myocardial infarction, mitigate the morphological changes linked to congestive heart failure, and offer treatments for end-stage renal disease. The technology is configured for percutaneous intravascular delivery of the pulsed electric fields, showcasing Levin's forward-thinking approach to medical technology.

Career Highlights

Howard R. Levin has garnered substantial experience through his work in various reputable companies. He has contributed significantly during his tenure with Medtronic Ardian Luxembourg S.a.r.l. and CHF Solutions, Inc. His extensive body of work continues to influence advancements in renal and cardiovascular treatments.

Collaborations

Throughout his career, Levin has collaborated with talented individuals in the field, including notable coworkers Mark Gelfand and Hanson Gifford. These collaborations have not only fostered innovation but have also helped bring transformative medical solutions to fruition.

Conclusion

In summary, Howard R. Levin stands out as a leading inventor in the medical technology sector, particularly in the area of renal neuromodulation. His 127 patents reflect a commitment to improving patient outcomes through innovative treatments. With continuous advancements in his work, Levin exemplifies the pivotal role that inventors play in the evolution of medical therapies.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…